| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Physiology, The University of Melbourne, Victoria 3010, Australia2 School of Agriculture, Charles Sturt University, Wagga Wagga, New South Wales 2678, Australia
The ß2-adrenoceptor agonist (ß2-agonist) fenoterol has potent anabolic effects on rat skeletal muscle. We conducted an extensive dose–response study to determine the most efficacious dose of fenoterol for increasing skeletal muscle mass in adult rats and used this dose in testing the hypothesis that fenoterol may have therapeutic potential for ameliorating age-related muscle wasting and weakness. We used adult (16-month-old) rats that had completed their growth and development, and old (28-month-old) rats that exhibited characteristic muscle wasting and weakness, and treated them daily with either fenoterol (1.4 mg kg-1, I.P), or saline vehicle, for 4 weeks. Following treatment, functional characteristics of fast-twitch extensor digitorum longus (EDL) and predominantly slow-twitch soleus muscles of the hindlimb were assessed in vitro. Untreated old rats exhibited a loss of skeletal muscle mass and a decrease in force-producing capacity, in both fast and slow muscles, compared with adult rats (P < 0.05). However, there was no age-associated decrease in skeletal muscle ß-adrenoceptor density, nor was the muscle response to chronic ß-agonist stimulation reduced with age. Thus, muscle mass and force-producing capacity of EDL and soleus muscles from old rats treated with fenoterol was equivalent to, or greater than, untreated adult rats. The increase in mass and strength was attributed to a non-selective increase in the cross-sectional area of all muscle fibre types, in both the EDL and soleus. Fenoterol treatment caused a small increase in fatiguability due to a decrease in oxidative metabolism in both EDL and soleus muscles, with some cardiac hypertrophy. Further studies are needed to fully separate the desirable effects on skeletal muscle and the undesirable effects on the heart. Nevertheless, our results demonstrate that fenoterol is a powerful anabolic agent that can restore muscle mass and strength in old rats, and provide preliminary evidence of therapeutic potential for age-related muscle wasting and weakness.
(Received 13 October 2003;
accepted after revision 14 November 2003;
first published online 14 November 2003)
Corresponding author G. S. Lynch: Department of Physiology, The University of Melbourne, Victoria 3010, Australia. Email: gsl{at}unimelb.edu.au
This article has been cited by other articles:
|
|
 |
|
  J. G. Ryall, J. D. Schertzer, T. M. Alabakis, S. M. Gehrig, D. R. Plant, and G. S. Lynch Intramuscular {beta}2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury J Appl Physiol, July 1, 2008; 105(1): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol J Appl Physiol, February 1, 2007; 102(2): 740 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Baker, D. Constantin-Teodosiu, S. W. Jones, J. A. Timmons, and P. L. Greenhaff Chronic Treatment with the beta2-Adrenoceptor Agonist Prodrug BRL-47672 Impairs Rat Skeletal Muscle Function by Inducing a Comprehensive Shift to a Faster Muscle Phenotype J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 439 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gregorevic, J. G. Ryall, D. R. Plant, M. N. Sillence, and G. S. Lynch Chronic {beta}-agonist administration affects cardiac function of adult but not old rats, independent of {beta}-adrenoceptor density Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H344 - H349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Plant, F. Beitzel, and G. S. Lynch Length-tension relationships are altered in regenerating muscles of the rat after bupivacaine injection J Appl Physiol, June 1, 2005; 98(6): 1998 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Schertzer, D. R. Plant, J. G. Ryall, F. Beitzel, N. Stupka, and G. S. Lynch {beta}2-Agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscle Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E526 - E533. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
